Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Capecitabine extends survival in triple-negative breast cancer

Key clinical point: For patients with early-stage triple-negative breast cancer, adding capecitabine to systemic treatment may extend overall survival.

Major finding: Among patients with triple-negative breast cancer, adding capecitabine to systemic treatment resulted in a 22% overall survival benefit (hazard ratio, 0.778).

Study details: An individual patient meta-analysis involving 15,457 patients with early-stage breast cancer.

Disclosures: The investigators reported relationships with Amgen, Lilly, Pfizer, and others.

Citation:

van Mackelenbergh M et al. SABCS 2019, Abstract GS1-07.